Roivant’s Priovant Therapeutics received FDA clearance for Lisraya (brepocitinib) to treat adults with dermatomyositis, marking another label win in a fast-moving rare-inflammation pipeline. The approval positions the once-daily oral JAK1/TYK2 inhibitor beyond earlier rare disease efforts and expands use for patients with an immunologic drivers profile. The regulatory step comes as competing cytokine-signaling approaches continue to mature, with JAK pathway modulation remaining central to multiple late-stage programs across rare autoimmune indications.